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Radiation therapy is one of the core components of multidisciplinary can-
cer care. Although 50% of all European cancer patients have an indica-~
tion for radiotherapy at least once in the course of their disease, more than
one out of four cancer patients in Europe do not receive the radiotherapy
they need. There are multiple reasons for this underutilisation, with limited
availability of the necessary resources in terms of both trained personnel–
and equipment being a major underlying cause of suboptimal access to–
radiotherapy. Moreover, large variations across European countries are
observed, not only in available radiotherapy equipment and personnel per
inhabitant or per cancer patient requiring radiotherapy, but also in work-
load. This variation is in part determined by the country’s gross national
income. Radiation therapy and technology are advancing quickly; hence,
recommendations supporting resource planning and investment should
reflect this dynamic environment and account for evolving treatment com-
plexity and fractionation schedules. The forecasted increase in cancer inci-
dence, the rapid introduction of innovative cancer treatments and the more
active involvement of patients in the healthcare discussion are all factors
that should be taken under consideration. In this continuously changing
oncology landscape, reliable data on the actual provision and use of radio-
therapy, the optimal evidence-based demand and the future needs are cru-
cial to inform cancer care planning and address and overcome the current
inequalities in access to radiotherapy in Europe.
1. Introduction
Radiotherapy is an essential part of the multidisci-
plinary treatment approach for a large number of can-
cer types. For individual patients, cancer care aims at
increasing cure rates, prolonging survival and/or
improving health-related quality of life (Ringborg,
2019). To realise the full impact of innovative interven-
tions on these outcomes and achieve the fundamental
aim of a mission-oriented approach to cancer, the
translation of clinical evidence into the healthcare sys-
tem is crucial and requires alignment over the entire
research spectrum, connecting the different compo-
nents of the cancer research continuum (Celis and
Pavalkis, ; Fiorino , ; Lievens, ;2017 et al. 2020 2017
Ringborg, ). There is still some work to be done2019
to attain this goal: in radiotherapy research, for exam-
ple, clinical and basic sciences by far dominate health
services research, the latter representing a mere 2% of
the entire radiotherapy research output worldwide
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(Aggarwal , ). Several gaps in late transla-et al. 2018
tional cancer research have been recognised: translat-
ing clinical trial data into real-life effectiveness and
cost-effectiveness evidence; developing guidelines,
including advices for data collection by cancer reg-
istries to facilitate outcomes research; and gathering
long-term outcomes and survivorship data.
In addition, the slow and variable implementation
of innovative treatment strategies into clinical practice
has been described as a major barrier leading to sub-
stantial inequalities in cancer care (Ringborg, ).2019
This may partly be attributed to the variation in avail-
ability of and access to the necessary healthcare
resources, which should be addressed (Sullivan ,et al.
2011). In cancer care, this implies that optimal provi-
sion and use of radiotherapy should be guaranteed, if
the aim is to achieve the best possible clinical out-
comes (Lievens , ). If radiotherapy could beet al. 2019b
deployed so that every cancer patient that requires
curative intent radiotherapy is granted access, this
would translate into one out of three patients achiev-
ing 5-year local tumour control and 5-year survival
benefits in one out 12 (Hanna , ). Worldwide,et al. 2018
closing the gap to radiotherapy by 2035 would allow
to save 1 million lives annually; beyond this curative
potential, radiotherapy also plays an important role in
alleviating symptoms such as pain, bleeding or
obstruction caused by the cancer (Atun , ).et al. 2015
Proper cancer care planning requires reliable data
on the actual situation, on the optimal evidence-based
demand, and on forecasted future needs, of treatments
as well as of the related human and capital resources
(Borras , ; WHO, ). The Health Eco-et al. 2015c 2002
nomics in Radiation Oncology project of the European
Society for Radiotherapy and Oncology (ESTRO-
HERO) has been developed to generate such evidence
for European countries, and focussed on the availabil-
ity, needs now and in the future and costs and– –
reimbursement of radiotherapy in Europe (Borras
et al. et al. et al., ; Borras2015a , ; Borras2016 , ;2015b
Defourny , ; Dunscombe , ; Grauet al. 2019 et al. 2014
et al. et al. et al., ; Lievens2014 , ; Lievens2014 , ;2020
Lievens and Grau, ). By benchmarking actual2012
data on resource availability and treatments delivered
with the optimal evidence-based needs, an estimation
of the gap between optimal and actual use of radio-
therapy by country has been made. Such data form
the basis for evidence-based policy decisions that
should be framed within a more integrated policy
action, such as National Cancer Control Plans (Borras
et al., ; WHO, ). Examples of similar analy-2015c 2002
ses and subsequent actions carried out at country level
– –for example in The Netherlands and Denmark
demonstrate the usefulness of such approach to effec-
tively cope with existing availability and access gaps
(Overgaard, 2015 ; Slotman and Vos, ).2013
In this Review article, we first address the needs for
and actual use of radiotherapy, and then describe the
actual provision of radiotherapy resources in Europe,
one of the main factors determining radiotherapy utili-
sation, to conclude with some policy recommendations
that could address the described gaps in use and provi-
sion.
2. Radiotherapy utilisation: balancing
evidence-based needs with actual use
2.1. How many radiation treatments are needed?
In order to evaluate the appropriateness of the actual
rate of radiotherapy utilisation in a given cancer popu-
lation, it is necessary to gain insight into the number
of radiation treatments that are needed to provide
optimal access to radiotherapy in specific countries or
geographic regions, or for separate tumour types. Two
methodologically distinct approaches are used.
The criterion-based benchmark (CBB) is an empiri-
cal approach that defines ‘gold-standard communities’,
which meet predetermined criteria for optimal access
(Mackillop , ). Thus, the defined optimal rateet al. 2015
of radiotherapy utilisation is then used as the bench-
mark to which all countries or regions should con-
form. The epidemiological evidence-based estimation
(EBEST), conversely, is a deductive approach derived
from evidence-based radiotherapy indications and epi-
demiological data, which combined allow estimating
an optimal radiotherapy utilisation for each indication
in the population of interest. The EBEST approach
may be limited to specific tumour types or encompass
the full spectrum of cancer diagnoses, the most well-
known example of the latter being the work of the
Collaboration for Cancer Outcomes Research and
Evaluation (CCORE) group in Australia (Barton
et al. et al. et al., ; Delaney2014 , ; Tyldesley2005 ,
2011).
As it is inherently difficult to define ‘gold-standard
communities’ across highly variable socio-economic
environments and regions, the CBB has limited appli-
cation in analyses considering multiple countries,
whereas the EBEST, due to its comprehensiveness and
applicability in various epidemiologic and socio-eco-
nomic contexts, has been used in programmes defining
optimal radiotherapy utilisation across Europe and
worldwide (Atun , ; Bentzen , ;et al. 2015 et al. 2005
Borras , ; Borras , ). Butet al. 2015a et al. 2015b
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irrespective of the approach used, some methodologic
considerations are required: longer time horizons used
for the analysis (e.g. several years to lifelong) typically
result in higher estimated needs than shorter time
frames (for example, 1 year after diagnosis); while
CBB analyses mostly predict lower needs than EBEST
studies, variation also occurs amongst different
EBEST models, related to the use of more or less
restrictive assumptions or different evidence and epi-
demiology input sources. Moreover, as exercises have
been performed in different time frames, in various
regions and for a range of tumour types, translating
into different treatment standards and cancer popula-
tion mixes, a range in optimal radiotherapy utilisation
figures has been reported in the literature (Atun ,et al.
2015 2014 2015a; Barton ,et al. ; Borras ,et al. ; Borras
et al. et al., ; Lievens2015b , ).2017
But regardless of these variations, the calculated
radiotherapy needs are converging to a quite consistent
average: 50% of all cancer patients have an indication
for radiotherapy at least once during the course of
their disease, irrespective of the world region evaluated
(Atun , ; Barton , ; Borras ,et al. 2015 et al. 2014 et al.
2015a 2015b 2017; Borras ,et al. ; Lievens ,et al. ).
2.2. Does the actual utilisation of radiotherapy in
Europe match the needs?
While the existing evidence suggests that one out of tw o
cancer patients has an indication for radiotherapy, the
actual radiot herapy util isation is muc h lower. Thi s is
especially true for the developing world, where many
countries have no radiotherapy equipment available –
hence no access – at all ( Atun et al., 2015). Underutilisa-
tion of radiotherapy is, how ever, not restrict ed to
low- and middle-income countries. In the pan-European
ESTRO-HERO project, the actual utilisation was com-
pared to the estimated optimal utilisation at country
level, suggesting a large discrepancy amongst European
countries. Less than 17% of European countries treat at
least 80% of the optimal indicat ions for radiotherapy,
and 46% of European countries t reat < 70% of the
patients with an indication for radiotherapy (Borras
et al., 2015b). This utilisation gap is evident even in
countries with good access to radiotherapy resources,
based on evidence from various European and other
high-income countries (Lievens et al., 2017). Figure 1
shows the heterogeneous distribution of access to radio-
therapy in Europe, calculated as the number of radio-
therapy machines per million inhabitants (left), or as the
number of radiotherapy machines per 10 000 patients
with an indication for radiotherapy (middle). Moreover,
how the actual utilisation of radiotherapy compares to
the evidence-based optimal utilisation i s presented on
the right. The fact that the ranking of countries from
low to high acces s vari es, depending on the de nominator
used, illustrates that accounti ng for the cancer incidence
and patient population in a count ry, rather than just the
number of inhabitants, affects the figures of megavoltage
(MV) machine availability.
There may be several reasons why patients forego
radiation treatment despite evidence-based recommen-
dations. Patient-related factors for radiation treatment
turndown include high comorbidity and age, low
socio-economic status and education, lack of aware-
ness and information on radiotherapy, and type of
Fig. 1. Access to radiotherapy in the European countries, calculated either as the available number of radiotherapy machines per million
inhabitants (A) or per 10 000 patients with an indication for radiotherapy (B). The right panel (C) shows the actual utilisation (AUP) of
radiotherapy relative to the evidence-based optimal use (OUP). Based on data from the ESTRO-HERO project (Borras , ; Borraset al. 2015a
et al. et al., ; Grau2015b , ).2014
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primary tumour (Asli , ; Goossens-Laanet al. 2018
et al. et al. et al., ; Lievens2014 , ; Sundaresan2017 ,
2017 2006a; Vulto ,et al. ). Moreover, physician-related
bias may apply, as provider characteristics and prefer-
ences vary, and specialists tend to recommend their
own treatment modalities (Vulto , ). Geo-et al. 2005
graphic factors, as travel distance to a radiotherapy
facility and living in rural areas, may also apply (Gab-
riel , ).et al. 2015
Insufficient infrastructures, including shortage of
human resources and/or equipment, waiting lists or
treatment delays, may also impact access to and use of
radiotherapy. Evolution of resource availability over
time has been shown to impact radiotherapy utilisation
in some jurisdictions, not in others (Asli , ;et al. 2014
Barton and Delaney, ). Finally, economic factors,2011
including provider costs, and reimbursement barriers
affect treatment decisions. It should not be neglected
that available methods to assess optimal radiotherapy
needs may be partially responsible for the observed
gap with actual use, as current models may be overes-
timating the needs. The relative importance of these
factors has not been studied in great detail so far.
In Norway, studies showed that radiotherapy use
increased significantly after the implementation of the
Norwegian Cancer Plan leading to increased radiother-
apy capacity (Asli , ; Asli , ). Theet al. 2014 et al. 2018
utilisation reached 42.5% in 2010 but was still lower
than the evidence-based optimum of 53%. For lung
and prostate cancer, the actual utilisation was consid-
erably lower than optimal, whereas in breast and rectal
cancer the actual use was close to the optimum, even
if still suboptimal. For palliative radiotherapy, the
Norwegian study found that utilisation was signifi-
cantly associated with factors such as household
income and the availability of a radiotherapy facility
at the diagnosing hospital, but even after adjustments
for such factors, unexplained geographic variations in
palliative radiotherapy utilisation existed. However,
expanding resources is not always sufficient for
increasing utilisation, as in New South Wales in Aus-
tralia radiotherapy utilisation remained stable over a
decade regardless of the resource investments made;
the new facilities could only just keep pace with the
increase in new cancer patients with an indication for
radiotherapy (Barton and Delaney, ).2011
In Belgium, the actual radiotherapy use and optimal
radiotherapy use were compared with the radiotherapy
advised during the multidisciplinary cancer team
(MDT) conferences in a total of 110 810 cancer
patients diagnosed in 2009 and 2010 (Lievens ,et al.
2017). The results showed that the overall utilisation
was 37%, significantly lower than the calculated
optimum of 53%, but in line with the advised radio-
therapy from the MDT (35%). Large variations by
tumour type were observed: for example, in lung and
prostate cancer the actual use was considerably lower
than the optimal, whereas in breast cancer or head
and neck cancer there was a reasonable concordance.
In addition, older age was also found to be a barrier
to radiotherapy utilisation. A similar negative impact
of older age on radiotherapy use was found in the
Netherlands. Moreover, whereas the utilisation of pri-
mary radiotherapy overall remained stable between
1988 and 2002 in the Netherlands, its use varied con-
siderably for certain tumour types in the same period,
reflecting evolving evidence (Vulto , ).et al. 2006b
The sparse data available thus suggest that the
radiotherapy use is lower than the evidence-based opti-
mum in most European countries. Further analysis of
explanations and barriers pertaining to specific coun-
tries is needed to better understand the role of radio-
therapy in modern multidisciplinary cancer
management in various jurisdictions and to plan for
future needs. One well-recognised and important bar-
rier is the lack of resources.
3. Radiotherapy resources available
across Europe
3.1. Provision of equipment
In 2013, the International Atomic Energy Agency pub-
lished a report on the available radiotherapy equip-
ment and unmet needs in 33 European countries
registered in their Directory of Radiotherapy Centres
(DIRAC) database (Rosenblatt , ). In total,et al. 2013
1286 active radiotherapy centres were reported. There
was a considerable variation in average number of
MV teletherapy machines per radiotherapy centre,
ranging between 1.2 and 7.0 across countries. A large
variation in department size was also observed, with
the largest centres (4 10 MV machines/centre) in Nor-–
dic countries, the United Kingdom, the Netherlands
and Slovenia, while western and southern European
countries had mostly small centres, typically with one
or two machines. The number of MV units per million
inhabitants also varied considerably (range: 1.3–
9.7 MV units per million), with under provision and
lower technical capabilities of the equipment seen espe-
cially in eastern and south-eastern European countries.
It was concluded that prevailing economic factors
affected the available infrastructure, and that the
observed fragmentation by itself may entail economic
burden, and impact the quality of radiotherapy.
4 Molecular Oncology (2020) 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.ª
Provision and use of radiotherapy Y. Lievens et al.
Printed by [U
niversiteitsbibliotheek G
ent - 193.191.170.002 - /doi/epdf/10.1002/1878-0261.12690] at [10/06/2020]. 
Page 4 of 10Provision and use of radiotherapy in Europe
10/06/2020https://febs.onlinelibrary.wiley.com/reader/content/10.1002/1878-0261.12690/format/pdf/...
While DIRAC collects data from departments on
voluntary basis, the ESTRO-HERO taskforce collected
radiotherapy resource data in Europe at country level,
through an 84-item web-based survey, which was com-
pleted through close interaction between the HERO
collaborators and the representatives of the National
Societies (NS) for radiation oncology in 40 European
countries (Dunscombe , ; Grau , ;et al. 2014 et al. 2014
Lievens , ). In this most recent dedicated sur-et al. 2014
vey on the provision of radiotherapy in Europe, an
equally large variation in available equipment and
number and size of departments amongst 28 European
countries was documented (Grau , ). Theet al. 2014
number of MV machines (cobalt, linear accelerators
and dedicated stereotactic machines) per million inhab-
itants ranged from 1.4 to 9.5 (median: 5.3) and the
average number of MV machines per department from
0.9 to 8.2 (median: 2.6). In many countries in southern
and central-eastern Europe, there was very limited
availability of radiotherapy machines overall and espe-
cially of the most updated equipment. The average
annual number of radiotherapy courses delivered per
MV unit was 419, but again with large variation
amongst countries (range: 262 1061). A clear relation–
to economic strength of the country was noted, a
lower gross national income (GNI) per capita predis-
posing for lower numbers of equipment per inhabitant
and for less advanced technologies, thus hampering
these countries to adopt the more innovative radio-
therapy treatments and techniques.
3.2. Provision of personnel
The collection of personnel data at national level, more
complex due to the different professional entities and
the more quickly changing data over time, was available
for 24 countries in the ESTRO-HERO project (Lievens
et al., ). It showed an average of 12.8 radiation2014
oncologists per million inhabitants, yet ranging between
extremes of 2.5 and 30.9. Similarly, large variability was
documented for the other personnel categories, with
averages (and ranges) of 7.6 (0–19.7) for physicis ts, 3.5
(2.7 12.6) for dosimetrists, 26.6 (1.9– –78) for radiation
therapists and 14.8 (0.4–61) for nurses, per million
inhabitants. To account for the fact that radiotherapy
professionals fulfil different roles and responsibilities in
various countries, further analysis was performed cate-
gorising the personnel on the basis of the tasks they
perform in the radiotherapy process. This, however,
had little impact on the ranges, with 20-fold variations
observed between the highest and lowest staffed coun-
tries. In terms of workload, radiation oncologists annu-
ally treated 209 courses on average (range: 100–350),
while the figures were 303 (85–758) for physicists and
dosimetrists combined, and 77 (26 157) for radiation–
therapists and nurses. Here too, patient throughput is
lower in countries with higher GNI/capita, especially
for the personnel working in treatment delivery, while
the availability of radiation oncologists and medical
physicists seems more influenced by other factors,
amongst others the tasks they are responsible for. As
radiation treatments require highly specialised personnel
for treatment preparation, delivery and quality assur-
ance, shortages can only be addressed by training the
required staff, which may take years to accomplish.
When observing such important variation in resource
availability and workload, one wonders how to explain
this, whether it is driven by significantly different needs
from different cancer populations to be served, and
whether the frequently used population-based denomi-
nator is the most appropriate. In addition, one could
question whether the actual situation is supported by
the available guidelines by country, and if so how?
3.3. Recommendations for radiotherapy staffing
and equipment
The QUARTS (RadioTherapy for Cancer: QUAnifica-
tion of Infrastructure and Staffing Needs) project, con-
ducted by ESTRO more than 15 years ago, provided
an overview of the available guidelines for radiotherapy
resource needs (Slotman ,et al. 2005). Bas ed on t he se , it
was suggested that one MV unit could serve 450
patients annually, whereas the personnel needs were
defined as one radiation oncologist per 200–250 patients
and one physicist per 450 500 patients. Already then,–
however, it was stressed that these are only crude guide-
lines, as the actual needs depend on cancer incidence,
population mix and treatment strategies, which may dif-
fer quite substantially across countries.
Recently, the ESTRO-HERO project updated these
recommendations used to support radiotherapy invest-
ments in 29 European countries (Dunscombe ,et al.
2014). It was quite sobering to see that after more than
a decade of clinical, technical and technological evolu-
tion in radiotherapy, many countries still used the
same guidelines, determined by the same numbers of
machine and personnel throughput. Yet, when com-
paring these recommendations to the available machi-
nes and personnel, it was clear that the latter typically
outpaced the number set forward by the guidelines,
indicating that the actual resources had been adjusted
to the needs of innovative and more complex radiation
treatments. This underscored the clear need for guide-
lines that incorporate variations in population and
treatment characteristics.
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As illustrated in Fig. , it is not trivial to consider1
cancer patients instead of the population to serve when
determining radiotherapy resource needs. Different
approaches have been reported in the literature.
Directory of Radiotherapy Centres-based analyses
have combined the number of patients who need radio-
therapy, estimated at 62.5% of incident cancers (50%
of patients for primary radiotherapy, 25% of these for
retreatment), with fixed estimates of treatment courses
per MV unit or personnel type as described above
(Datta ,et al . 20 14; R os enbl at t et al., 2013).
An already more refined approach was used by the
ESTRO-QUARTS project, combining a similar fixed
MV machine throughput of 450 courses per year with
the epidemiology and clinical evidence on proportions
of patients who require radiotherapy for different can-
cer types, following the CCORE-EBEST methodology.
As such, the differences in MV machines required per
million inhabitants were assessed amongst 25 Euro-
pean countries, resulting in an average number of 5.9,
yet ranging between 4.0 and 8.1 (Bentzen , ).et al. 2005
Hence, radiotherapy resource needs are indeed, at least
partly, driven by cancer incidence and population mix.
Recently, the ESTRO-HERO project has developed
a time-driven activity-based costing model for external
beam radiotherapy (Defourny , ). This modelet al. 2019
not only allows calculating radiotherapy costs, but also
allows estimating the quantity of equipment and
human resources needed to treat a specific cancer pop-
ulation with radiotherapy. By accounting for the speci-
ficities of the population to be treated (proportion of
various cancer types, curative vs. palliative intent),
combined with complexity and fractionation schedules
in clinical use in a country, it estimates the number of
radiotherapy resources needed in a more granular
manner. In addition, the consequences of changing
cancer populations (e.g. due to the instauration of
screening programmes) and of varying treatment indi-
cations, complexities and fractionation schedules can
be assessed, thus forecasting future needs. As such,
this model provides an additional and more versatile
tool to determine personnel and equipment needs,
complementing the more static recommendations of
resources needed per number of treatment courses or
per population.
4. The broader picture of
policymaking for the future of
radiotherapy provision and use
With increasing pressure on healthcare budgets in
most European countries, the radiation oncology com-
munity needs to get better insight into the equipment
and personnel required to deliver safe, high-quality
and innovative radiotherapy to all cancer patients who
need it (Dunscombe , ). Meanwhile, the largeet al. 2014
variations observed across Europe in radiotherapy
resource provision and use, and the fact that available
radiotherapy resources by country, and their utilisa-
tion, are partly related to the countries’ GNI instead
of actual clinical needs clearly indicates that policy
decisions about investment matter.
Three major factors are expected to be drivers of
cancer policymaking for the coming years. First, the
number of cancer patients is growing, due to an
increasing cancer incidence, which is related, amongst
others, to the ageing of the population in Europe (Bor-
ras , ; Overgaard, ). The fact that agedet al. 2016 2015
patients usually have a higher probability of comorbid-
ity stresses the need for a truly multidisciplinary
approach to clinical decision-making (Stairmand ,et al.
2015). The increasing number of cancer patients amen-
able to radiotherapy also underscores that recommen-
dations should move away from simple population-
based approaches to models that integrate real patient
numbers and evolving practice patterns (Dunscombe
et al., ).2014
Second, the continuous introduction of new thera-
peutic and technological advances imposes various
challenges upon the healthcare system. The impact of
innovations on the quality of care and clinical out-
comes needs to be rapidly assessed, and this is more
difficult to accomplish for devices than for pharmaceu-
tical interventions, as the assessment has to be per-
formed prior to or in the early stages of
implementation, when access is still limited (Lievens,
2017 2019a 2017; Lievens ,et al. ; Smith ,et al. ). More-
over, healthcare systems need to be made sustainable,
also in high-income regions such as Europe: the grow-
ing annual increase in cancer costs is one of the main
risks to the future financing of health care (Sullivan
et al., ). To this end, the combination of new tech-2011
nologies, new drugs and new indications for existing
therapies poses a problem without simple answers.
Finally, the more active role of patients is changing
the traditional patient physician relationship in the–
healthcare setting (Leech , ). The perspectiveet al. 2020
of the patient should be considered when analysing the
planning of cancer care.
These factors are deemed to also impact radiother-
apy provision and utilisation. While the introduction
of novel technologies is recognised as one of the dri-
vers of the increasing healthcare costs, the require-
ments of health technology assessment for medical
devices in Europe lag behind those for drugs (Lievens,
2017 2019a; Lievens ,et al. ). Market entry of new high-
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end radiotherapy technologies with higher investment
and operational costs, of which particle therapy and
magnetic resonance-guided radiotherapy are typical
examples (Grau , ), urges policymakers toet al. 2020
address this issue. Meanwhile, approaches such as
managed entry agreements could help to guarantee
early patient access to new technologies that have
shown consistent and promising data from the initial
stages of clinical application (Morel , ). Real-et al. 2013
world data, including patient-reported outcome and
experience measures, may offer additional insight on
the clinical effectiveness of new therapeutic devices
(Lievens , ).et al. 2019a
Moreover, radiation oncology needs to be fully inte-
grated into national cancer plans (Borras ,et al.
2015c). It is only feasible to address the challenges
effectively if we are able to discuss how cancer services
should be organised, and how many resources are
needed to provide optimal access to all European citi-
zens to high-quality cancer care. This discussion
should be carried out within the framework of a can-
cer plan, as has been supported by the European Com-
mission and countries through the Joint Actions
Against Cancer (https://www.ipaac.eu/).
Cancer policy, like any healthcare policy, involves
making decisions that combine high levels of uncer-
tainty and expectations: uncertainty about whether the
actual clinical benefit of innovations will match the
expectations, and related uncertainty about the actual
resources needed to provide access to these innova-
tions. While clinical trials remain the mainstay of evi-
dence generation, they are often more difficult to
perform in the context of locoregional cancer strategies
(Lievens , ). Real-world data could form theet al. 2019a
bridge between expectations and clinical efficacy and
effectiveness, and provide an additional approach to
evidence generation in rapidly evolving environments
such as radiation oncology. In parallel, there is also a
need to generate evidence on how to organise health-
care provision and delivery, to optimise access for can-
cer patients in Europe. These new types of evidence
can be generated by so-called late translational
research, assessing the dissemination of new technolo-
gies, their provision and utilisation, their quality and
impact on outcomes (Ringborg, ). Only when bas-2019
ing policymaking on this kind of data from across
Europe, it would serve the best interests of all Euro-
pean cancer patients.
5. Conclusion
While about 50% of all cancer patients have an evi-
dence-based indication for radiotherapy, more than
one out of four cancer patients in Europe do not have
access to the radiotherapy they need. Although the
reasons underlying this underuse of radiotherapy are
multifactorial, the insufficient and highly variable pro-
vision of radiotherapy resources, personnel as well as
equipment, is one of the main challenges. There is an
urgent need to generate more evidence to understand
and address the current inequalities in radiotherapy
provision and use across Europe, and leverage these
data to support multidisciplinary cancer management,
cancer planning and policymaking. Only by doing so,
we may succeed in providing optimal radiation treat-
ment to every individual cancer patient in Europe,
regardless of where he or she lives.
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